Current progress on farnesyl protein transferase inhibitors

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 225-244

  Singh, Sheo B ^a   Lingham, Russell B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticancer agents; Clinical and preclinical data; Farnesyl protein transferase; FPTase inhibitors; Merck FPTase inhibitors; Natural products; Prenyltransferase

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ARTANOMALOIDE; ARTEMINOLIDE; ARTEMINONE; AZD 3409; BIM 46228; CAPECITABINE; CHAETOMELLIC ACID A; CHAETOMELLIC ACID B; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LB 42908; LONAFARNIB; MYCOTRIENIN II; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; NL 2001; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; TIPIFARNIB; TOPOTECAN; TRANSFERASE INHIBITOR; TRASTUZUMAB; UCF 116; UNCLASSIFIED DRUG; UNINDEXED DRUG; XR 3054;

ANIMAL CELL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; MOUSE; NEUTROPENIA; NONHUMAN; POLYDIPSIA; REVIEW;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ENZYME INHIBITORS; HUMANS;

EID: 0036489947     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Inhibitors of protein prenylation 2000
2. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyl-transferase inhibitor
3. Role of mitochondria in apoptosis induced by BMS-214662, an unusually apoptotic farnesyltransferase inhibitor
4. Potential dual mechanism of action for BMS-214662, a member of the benzodiazepine class farnesyltransferase inhibitors
5. Phase I clinical trials of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
6. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyl-transferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
7. Pharmacokinetics-antitumor activity relationship of BMS-214662, a novel inhibitor of farnesyltransferase
8. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors
9. Dose escalation study of oral farnesyl transferase inhibitor (FTI) BMS-214662 in patients with solid tumors
10. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (pts) with advanced solid tumors: Clinical findings
11. Phase I study of farnesyl transferase inhibitor, BMS-214662 in solid tumors
12. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors
13. A phase I dose escalating study of BMS-214662 in combination with cisplatin in patients with advanced solid tumors
14. K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
15. Direct demonstration of geranylgeranylation and farnesylation of Ki-ras in vivo
16. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
17. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer
18. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777, in patients with advanced solid tumors
19. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial
20. Inhibition of HDJ2 protein farnesylation in peripheral blood mononuclear cells as a pharmacodynamic endpoint in a phase I study of R115777 and gemcitabine
21. A phase I pharmacokinetic (PK) and biological study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (pts) with advanced solid malignancies
22. A phase I trial of the farnesyltransferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
23. A phase I clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: A promising combination in patients (pts) with solid tumors
24. Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor (FTI) R115777
25. Enhanced myelosuppression of topetecan when combined with the farnesyl transferase inhibitor, R115777: A phase I and pharmacodynamic study
26. A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer
27. Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor (FTI) R115777
28. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
29. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336
30. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH66336 given twice daily to patients with advanced solid tumors
31. Induction therapy with SCH66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of head and neck
32. NCIC CTG IND. 128: A phase II study of a farnesyl transferase inhibitor (SCH66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy
33. Randomized phase II study of SCH66336 and gemcitabine in the treatment of metastatic adenocarcinoma of pancreas
34. Synthesis of the major metabolite and impurities in the bulk drug synthesis of ABT-839 (farnesyl transferase inhibitor)
35. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyl-transferase, BIM-46228
36. Synthesis and structure-activity relationships of 1-(1(3)H-imidazole-5(4)-yl)methylpyrroles as farnesyl protein transferase inhibitors (FPTI)
37. Farnesyltransferase inhibitors (FTI's) block transition of G1/s phase by down regulation of cyclin A, cyclin dl and MAPK
38. A novel class of highly potent, selective, and non-peptidic inhibitor of ras farnesyltransferase (FTase)
39. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase
40. Farnesyl-protein transferase: A new paradigm for cancer chemotherapy, advances in discovery and development of natural product inhibitors
41. Non-peptidic prenyltransferase inhibitors: Diverse structural classes and surprising anti-cancer mechanisms
42. Arteminolide, an inhibitor of farnesyl transferase from Artemisia sylvatica
43. Sesquiterpene lactone, inhibitors of farnesyl protein transferase, isolated from the flower of Artemisia sylvatica
44. UCF116, new inhibitors of farnesyltransferase produced by Streptomyces
45. Inhibitory activity to protein prenylation and antifungal activity of zaragozic acid D3, a potent inhibitor of squalene synthase produced by fungus, Mollisia sp. SANK 10294
46. XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase
47. Isolation and structure of chaetomellic acids A and B from Chaetomella acutiseta: Farnesyl pyrophosphate mimic inhibitors of Ras farnesyl-protein transferase
48. Efficient syntheses, human and yeast farnesyl-protein transferase inhibitory activities of chaetomellic acids and analogues
49. Chemoselective carbon-carbon coupling of organocuprates with (bromomethyl)methylmaleic anhydride: Synthesis of chaetomellic acid A
50. Clavaric acid: A triterpenoid inhibitor of farnesyl-protein transferase from Clavariadelphus truncatus
51. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase
52. Inhibition of purified p21 ras farnesyl: Protein transferase by Cys-AAX tetrapeptides
53. Polyisoprenylation of Ras in vitro by a farnesyl-protein transferase
54. Pseudopeptide inhibitors of farnesyl-protein transferase
55. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
56. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
57. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
58. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
59. Synthesis and biological activity of Ras farnesyl protein transferase inhibitors. Tetrapeptide analogs with amino methyl and carbon linkages
60. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase
61. Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase
62. Phenol based tripeptide inhibitors of ras farnesyl protein transferase
63. Potent, non-thiol inhibitors of farnesyltransferase
64. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase
65. Pseudodipeptide inhibitors of protein farnesyltransferase
66. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase
67. N-Arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
68. Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase
69. Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I
70. Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl} imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency
71. Synthesis of conformationally constrained 5,6,7,8-tetrahydroimidazo [1,5-a]pyridine inhibitors of farnesyltransferase
72. Conformational restriction of flexible ligands guided by the transferred nOe experiment: Potent macrocyclic inhibitors of farnesyltransferase
73. Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase
74. 3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: Synthesis of a conformationally restricted inhibitor of farnesyltransferase
75. Diarylether inhibitors of farnesyl-protein transferase
76. Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase
77. Diaryl ether inhibitors of farnesyl-protein transferase
78. Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
79. 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase
80. Functional organization of the yeast proteome by systematic analysis of protein complexes
81. Systematic identification of protein complexes in saccharomyces cerevisiae by mass spectrometry